OncoSec Medical Incorporated’s recently made public that its VP, Finance DelAversano Robert J unloaded Company’s shares for reported $55.0 on Feb 09. In the deal valued at $1.37 per share,40 shares were sold. As a result of this transaction, DelAversano Robert J now holds 1,008 shares worth roughly $ 1088.64.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Then, DelAversano Robert J sold 283 shares, generating $105 in total proceeds. Upon selling the shares at $0.37, the VP, Finance now owns 22,975 shares.
Before that, DelAversano Robert J sold 284 shares. OncoSec Medical Incorporated shares valued at $202 were divested by the VP, Finance at a price of $0.71 per share. As a result of the transaction, DelAversano Robert J now holds 23,258 shares, worth roughly $25118.640000000003.
BTIG Research initiated its OncoSec Medical Incorporated [ONCS] rating to a Buy in a research note published on Tuesday, March 08, 2021; the price target was $10. PT values the company’s stock at a premium of 89.2 to its Tuesday closing price. A number of analysts have revised their coverage, including Dawson James’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering ONCS and has decreased its forecast on November 07, 2018 with a “Neutral” recommendation from previously “Buy” rating. Piper Jaffray started covering the stock on February 09, 2018. It rated ONCS as “an Overweight”.
Price Performance Review of ONCS
On Tuesday, OncoSec Medical Incorporated [NASDAQ:ONCS] saw its stock fall -4.42% to $1.08. On the same session, the stock had its day’s lowest price of $0.97, but rose to a high of $1.14. Over the last five days, the stock has lost -0.92%. OncoSec Medical Incorporated shares have fallen nearly -35.71% since the year began. Nevertheless, the stocks have fallen -94.74% over the past one year. While a 52-week high of $31.90 was reached on 01/17/23, a 52-week low of $0.74 was recorded on 02/23/23. SMA at 50 days reached $1.7794, while 200 days put it at $9.9626. A total of 0.81 million shares were traded, compared to the trading of 1.42 million shares in the previous session.
Levels Of Support And Resistance For ONCS Stock
The 24-hour chart illustrates a support level at 0.9867, which if violated will result in even more drops to 0.8933. On the upside, there is a resistance level at 1.1567. A further resistance level may holdings at 1.2333. The Relative Strength Index (RSI) on the 14-day chart is 34.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1000, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 65.11%. Stochastics %K at 43.04% indicates the stock is a holding.
How much short interest is there in OncoSec Medical Incorporated?
A steep rise in short interest was recorded in OncoSec Medical Incorporated stocks on Jan 12, 2023, dropping by 70240.0 shares to a total of 44430.0 shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 0.11 million shares. There was a decline of -158.09%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 2.01% of the overall stock float, the days-to-cover ratio (short ratio) fell to 0.14.
OncoSec Medical Incorporated [ONCS] – Who Are The Largest Shareholders?
In filings from SSgA Funds Management, Inc., it is revealed that the company now owns 25,187 shares, or roughly 0.85% of the outstanding ONCS shares. In other words, the investor’s shares have risen by 23,199 from its previous 13-F filing of 1988.0. Additionally, Renaissance Technologies LLC increased 689.13% of its stake after which the total value it holdings stand at $53,194. Over the last quarter, Benjamin Partners, Inc. purchased 7,332 shares of OncoSec Medical Incorporated, while The Bank of New York Mellon Corp bought 1 shares. At present, Virtu Financial BD LLC is holding 12,987 shares valued at $28571.0. Geode Capital Management LLC owned 12,498 shares of the company at the time of its most recent 13F filing, worth $27496.0.